Literature DB >> 22147257

Effect of PDE10A inhibitors on MK-801-induced immobility in the forced swim test.

Barbara Langen1, Rita Dost, Ute Egerland, Hans Stange, Norbert Hoefgen.   

Abstract

RATIONALE: Negative symptoms of schizophrenia are insufficiently treated by current antipsychotics. However, research is limited by the lack of validated models. Clinical data indicate that phencyclidine (PCP) abuse may induce symptoms resembling negative symptoms in humans. Based on that, Noda et al. proposed a model of PCP-induced increase of immobility in the forced swim test in mice as a model of depression-like negative symptoms of schizophrenia.
OBJECTIVES: The aim of the study was to evaluate the effect of phosphodiesterase 10A (PDE10A) inhibition in this model which was modified by using MK-801 instead of PCP.
METHODS: Increase of immobility in the forced swim test was induced by repeated MK-801 treatment followed by a 2-day washout in mice. The effect of haloperidol, clozapine, risperidone and PDE10A inhibitors was evaluated in this model, on open-field activity and acute MK-801-induced hyperactivity.
RESULTS: Repeated MK-801 treatment significantly increased immobility in the forced swim test without affecting open-field activity. It induced hypersensitivity to the dopamine D1 agonist A-68930, suggesting a hypofunction of the D1 pathway. The increase of immobility is reversed by clozapine and PDE10A inhibitors, but not by haloperidol. Clozapine and the PDE10A inhibitors did not enhance activity at effective doses.
CONCLUSION: The possibility to substitute PCP by MK-801 in this model indicates that the effect is mediated by their common mechanism of NMDA antagonism. PDE10A inhibitors similar to clozapine significantly antagonize the increase of immobility, suggesting a therapeutic potential for the treatment of negative symptoms. However, further validation of the model is necessary.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22147257     DOI: 10.1007/s00213-011-2567-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  43 in total

1.  Treatment of adolescent phencyclidine (PCP) abusers.

Authors:  G G De Angelis; E Goldstein
Journal:  Am J Drug Alcohol Abuse       Date:  1978       Impact factor: 3.829

2.  Characterization in rats of the anxiolytic potential of ELB139 [1-(4-chlorophenyl)-4-piperidin-1-yl-1,5-dihydro-imidazol-2-on], a new agonist at the benzodiazepine binding site of the GABAA receptor.

Authors:  Barbara Langen; Ute Egerland; Katrin Bernöster; Rita Dost; Klaus Unverferth; Chris Rundfeldt
Journal:  J Pharmacol Exp Ther       Date:  2005-04-28       Impact factor: 4.030

3.  Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine.

Authors:  J Kane; G Honigfeld; J Singer; H Meltzer
Journal:  Arch Gen Psychiatry       Date:  1988-09

Review 4.  Schizophrenia: genesis, receptorology and current therapeutics.

Authors:  B Capuano; I T Crosby; E J Lloyd
Journal:  Curr Med Chem       Date:  2002-03       Impact factor: 4.530

5.  Differential regulation of the NMDA receptor by acute and sub-chronic phencyclidine administration in the developing rat.

Authors:  Noelle C Anastasio; Kenneth M Johnson
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

6.  Phosphodiesterase 10A inhibition modulates the sensitivity of the mesolimbic dopaminergic system to D-amphetamine: involvement of the D1-regulated feedback control of midbrain dopamine neurons.

Authors:  Florence Sotty; Liliana P Montezinho; Björn Steiniger-Brach; Jacob Nielsen
Journal:  J Neurochem       Date:  2009-02-19       Impact factor: 5.372

7.  Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis.

Authors:  J W Newcomer; N B Farber; V Jevtovic-Todorovic; G Selke; A K Melson; T Hershey; S Craft; J W Olney
Journal:  Neuropsychopharmacology       Date:  1999-02       Impact factor: 7.853

8.  Clinical and biologic response to clozapine in patients with schizophrenia. Crossover comparison with fluphenazine.

Authors:  D Pickar; R R Owen; R E Litman; E Konicki; R Gutierrez; M H Rapaport
Journal:  Arch Gen Psychiatry       Date:  1992-05

Review 9.  The NMDA antagonist model for schizophrenia: promise and pitfalls.

Authors:  W M Abi-Saab; D C D'Souza; B Moghaddam; J H Krystal
Journal:  Pharmacopsychiatry       Date:  1998-07       Impact factor: 5.788

10.  Assessing cognitive function in clinical trials of schizophrenia.

Authors:  Jennifer H Barnett; Trevor W Robbins; Verity C Leeson; Barbara J Sahakian; Eileen M Joyce; Andrew D Blackwell
Journal:  Neurosci Biobehav Rev       Date:  2010-01-25       Impact factor: 8.989

View more
  5 in total

1.  Phosphodiesterase 10A inhibitor MP-10 effects in primates: comparison with risperidone and mechanistic implications.

Authors:  Subramaniam Uthayathas; Gunasingh J Masilamoni; Christopher L Shaffer; Christopher J Schmidt; Frank S Menniti; Stella M Papa
Journal:  Neuropharmacology       Date:  2014-02       Impact factor: 5.250

2.  A Natural Product with High Affinity to Sigma and 5-HT7 Receptors as Novel Therapeutic Drug for Negative and Cognitive Symptoms of Schizophrenia.

Authors:  Lien Wang; Yan Zhang; Chaoran Wang; Xiuli Zhang; Zhiwei Wang; Xinmiao Liang; Amal Alachkar; Olivier Civelli
Journal:  Neurochem Res       Date:  2019-09-16       Impact factor: 3.996

3.  Striatal phosphodiesterase 10A and medial prefrontal cortical thickness in patients with schizophrenia: a PET and MRI study.

Authors:  R Bodén; J Persson; A Wall; M Lubberink; L Ekselius; E-M Larsson; G Antoni
Journal:  Transl Psychiatry       Date:  2017-03-07       Impact factor: 6.222

4.  Galphimia glauca and Natural Galphimines Block Schizophrenia-Like Symptoms Induced with Apomorphine and MK-801 in Mice.

Authors:  Mayra Alejandra Santillán-Urquiza; Maribel Herrera-Ruiz; Alejandro Zamilpa; Enrique Jiménez-Ferrer; Rubén Román-Ramos; Elian Yuritzi Alegría-Herrera; Jaime Tortoriello
Journal:  Evid Based Complement Alternat Med       Date:  2019-07-21       Impact factor: 2.629

5.  Involvement of GABAB Receptor Signaling in Antipsychotic-like Action of the Novel Orthosteric Agonist of the mGlu4 Receptor, LSP4-2022.

Authors:  Monika Woźniak; Francine Acher; Marcin Marciniak; Magdalena Lasoń-Tyburkiewicz; Piotr Gruca; Mariusz Papp; Andrzej Pilc; Joanna M Wierońska
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.